ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LCTX vs LXEO // ENTERPRISE SCALE & MARKET CAP

Lineage Cell Therapeutics Inc. (NYSE) VS. Lexeo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LCTX 3 — LXEO 0
▲ ENTERPRISE SCALE & MARKET CAP LEADER: LCTX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LCTX VS. LXEO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LCTX LXEO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.46% — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 53.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 LCTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.8 48.3 +2.54 LCTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $260.5M $251.1M $9.4M LCTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LCTX REV LXEO REV LCTX GROSS % LXEO GROSS % LCTX FCF LXEO FCF
FY 2025 $14.6M $0 — — -$19.4M -$99.0M
FY 2024 $9.5M $0 96.5% — -$23.7M -$81.6M
FY 2023 $8.9M $0 — — -$28.6M -$59.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LCTX // BETA —
LXEO // BETA —